BeSound Breast

Cover Block

Attribute	Value
Name	BeSound Breast
Tagline	Advanced breast imaging platform combining ultrasound and photoacoustic imaging for earlier cancer detection.
Headquarters	Los Angeles, CA, USA
Founded	2025
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology	Medical Imaging, AI
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed
Total Disclosed	$6.8M

Links

• Website: https://www.besoundbreast.com
• LinkedIn: https://www.linkedin.com/in/baileyrenger/

Data Accuracy: GREEN -- Company website and founder's LinkedIn profile are publicly accessible and confirmed.

Executive Summary

BeSound Breast is a seed-stage healthtech company that has secured $6.8 million to commercialize a breast imaging platform designed to address a specific, underserved segment of the screening market: younger women and those with dense breast tissue [Fortune, September 2025]. The company's wedge is a combination of ultrasound and photoacoustic imaging, a hybrid modality intended to improve detection specificity and reduce false positives compared to traditional mammography or ultrasound alone [Perplexity Sonar Pro Brief].

Founder Bailey Renger, a 26-year-old with a background in quantum physics, launched the company to create a more accessible screening option [Fortune, September 2025] [Bizwomen]. The core offering is a direct-to-consumer service, with scans priced at a fixed, out-of-pocket fee of $350 and results delivered within 24 to 48 hours [Perplexity Sonar Pro Brief].

The company is currently deploying its seed capital to expand from its flagship Los Angeles clinic, with plans for a mobile unit, a New York location, and deeper integration with partner OB/GYN practices [Femtech Insider]. The next 12 to 18 months will test the scalability of this capital-intensive clinical rollout and the broader adoption of its consumer-pay model.

Data Accuracy: GREEN -- Core claims (funding, product, founder) confirmed by multiple independent sources including Fortune and company materials.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed $6,800,000)

How the Company Got Here

BeSound Breast was founded in 2025 by Bailey Renger, a 26-year-old entrepreneur who launched the company to address a personal and systemic gap in breast cancer screening for younger women and those with dense breast tissue [Fortune, September 2025]. The company is headquartered in Los Angeles, California, and operates its flagship clinic at 8274 Melrose Avenue [BeSound Breast].

Its primary operational milestone to date is the September 2025 closing of a $6.8 million seed round, led by Village Global and Khosla Ventures with participation from The Helm, XFactor Ventures, and January Ventures [Fortune, September 2025]. This capital is intended to fund the expansion of its clinic footprint, including a planned New York City location and mobile units for underserved regions [Femtech Insider].

Data Accuracy: YELLOW -- Core facts (founding year, founder, funding) are confirmed by a primary news source. Headquarters and operational status are cited from the company's own materials.

Product and Technology

BeSound's commercial wedge is a consumer-facing imaging service, but its technical differentiation rests on a hybrid hardware and software platform. The company offers a breast-imaging platform that combines ultrasound and photoacoustic imaging [BeSound Breast]. This combination is central to its pitch for improving detection in dense breast tissue. The service provides imaging plus results in 24-48 hours for a fixed, out-of-pocket fee of $350 per scan [Perplexity Sonar Pro Brief]. The company currently operates a flagship clinic in Los Angeles and has publicly announced plans for a New York location and mobile units to reach underserved regions [Femtech Insider, Perplexity Sonar Pro Brief].

The platform uses AI-powered ultrasound scans that are radiation-free [f4.fund]. Company materials state it is developing advanced ultrasound with proprietary, real-time, AI-assisted analysis [BeSound Breast]. On the commercial side, the model is dual-pronged: it sells directly to consumers booking scans online and partners with OB/GYN and other medical practices to integrate its technology into their offices, with scans interpreted by independent physician groups [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core product claims are consistent across company sources and press, but specific technical performance metrics are unverified.

Where the Demand Sits

BeSound's core market is defined by the limitations of traditional mammography. Mammograms are the standard screening tool, but their sensitivity drops significantly in dense breast tissue, a condition affecting an estimated 40-50% of women [American Cancer Society]. This creates a substantial population of women, particularly those under 40 who are not yet eligible for routine mammography under many guidelines, who are poorly served by the current standard of care.

Demand is driven by growing state-level legislation mandating that patients be notified of their breast density status [American College of Radiology]. Furthermore, a trend toward patient-directed healthcare and consumer-friendly medical services supports BeSound's direct-to-consumer model with transparent pricing and rapid results.

Key adjacent and substitute markets include the broader breast imaging and diagnostic sector. BeSound's technology, combining ultrasound with photoacoustic imaging, positions it within the advanced ultrasound segment, which competes with automated whole-breast ultrasound systems from established players like GE HealthCare and Siemens Healthineers. The company's $350 out-of-pocket fee also places it in direct competition with other cash-pay screening services and advanced diagnostic centers.

While the company currently operates on a cash-pay model, long-term scale likely depends on securing insurance coverage or Medicare/Medicaid reimbursement for its scans. The global breast imaging market was valued at approximately $4.5 billion in 2023 and is projected to grow at a compound annual rate of around 8% [Grand View Research, 2024].

Data Accuracy: YELLOW -- Market sizing is drawn from analogous, broad industry reports. Specific demand drivers are well-established in medical literature.

Competitive Landscape

BeSound Breast enters a market where the primary competition is not other startups but the entrenched standard of care and the reimbursement structures that support it.

Company	Positioning	Stage / Funding	Notable Differentiator
BeSound Breast	Direct-to-consumer advanced imaging (ultrasound + photoacoustic) for dense breasts & younger women.	Seed ($6.8M, 2025)	Consumer-pay model ($350/scan), 24-48 hr results, mobile unit plans.
iSono Health	At-home, automated 3D breast ultrasound for monitoring high-risk patients.	Series A ($7M, 2022)	Wearable, at-home form factor enabling patient-administered scans.
Delphinus	Automated whole-breast ultrasound (ABUS) system for dense breast screening, sold to imaging centers.	Later stage (acquired by Hologic, 2021)	FDA-cleared, reimbursed technology integrated into hospital radiology workflows.
Seno Medical	Opto-acoustic (photoacoustic) imaging for breast cancer diagnosis, focusing on lesion characterization.	Commercial stage (FDA PMA 2021)	Focus on improving diagnostic specificity to reduce unnecessary biopsies.

Competition unfolds across three distinct segments: the incumbent mammography ecosystem, adjacent diagnostic technologies, and challenger technologies targeting mammography's limitations. BeSound's defensible edge today rests on its consumer-first distribution and pricing model. While competitors sell hardware to providers or seek complex insurance approvals, BeSound offers a fixed-price, cash-pay service directly to patients, bypassing reimbursement friction entirely.

Data Accuracy: YELLOW -- Competitor profiles compiled from public company materials and industry databases; BeSound's positioning is confirmed by primary sources.

Opportunity

The potential outcome for BeSound is the creation of a new, widely adopted standard for supplemental breast cancer screening, particularly for younger women and those with dense breast tissue.

Scenario	What happens	Catalyst
National Clinic & Mobile Network	BeSound scales its flagship model into a nationwide chain of owned clinics and mobile units.	Successful deployment of mobile units to rural and underserved regions, coupled with the launch of a New York City location.
Embedded Practice Standard	BeSound's technology becomes the default supplemental imaging tool integrated into thousands of OB/GYN and primary care practices nationwide.	A major partnership with a large physician network or healthcare system to white-label or co-brand the service.
Guideline & Reimbursement Shift	Clinical data from BeSound's platform contributes to updated screening guidelines, leading to widespread insurance coverage.	Publication of peer-reviewed studies demonstrating improved outcomes in dense-breast populations.

To size the win, investors can look to public comparables in the women's health and diagnostic imaging space. Hologic (HOLX), a leader in breast health diagnostics, currently holds a market capitalization of approximately $18 billion. While BeSound is at an early stage, a scenario where it captures a meaningful portion of the supplemental screening market for dense breast tissue could support a valuation significantly above its current seed post-money valuation [Caplight, September 2025].

Data Accuracy: YELLOW -- Opportunity framing is based on confirmed product claims and expansion plans; market outcome scenarios are plausible extrapolations.

Sources

1. [Fortune, September 2025] BeSound raises $6.8 million for breast cancer screening | https://fortune.com/2025/09/30/besound-fundraise-breast-cancer-ultrasound-screening-mammograms-oura
2. [Bizwomen] She Couldn’t Get A Breast Cancer Scan. So She Built One For Women | https://www.bizjournals.com/bizwomen/news/latest-news/2025/10/she-couldnt-get-a-breast-cancer-scan-so-she-built.html
3. [BeSound Breast] BeSound Breast | https://www.besoundbreast.com/
4. [BeSound Breast] Technology - BeSound Breast Health | https://www.besoundbreast.com/technology
5. [BeSound Breast] FAQs - BeSound Breast Health | https://www.besoundbreast.com/faqs
6. [f4.fund] BeSound, Healthcare & Digital Health | https://f4.fund/startups/besoundbreast
7. [Femtech Insider] BeSound Raises $6.8M to Expand Breast Cancer Screening for Dense Tissue and Younger Women | https://femtechinsider.com/besound-raises-6-8m-to-expand-breast-cancer-screening-for-dense-tissue-and-younger-women/
8. [Caplight, September 2025] BeSound Breast company profile | https://caplight.com/company/besound-breast
9. [American Cancer Society] Breast Cancer Facts & Figures | https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
10. [American College of Radiology] Dense Breast Tissue and Supplemental Screening | https://www.acr.org/Practice-Management-Quality-Informatics/Imaging-3/Case-Studies/Breast-Imaging/Dense-Breast-Tissue-and-Supplemental-Screening
11. [Grand View Research, 2024] Breast Imaging Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/breast-imaging-market
12. [Tracxn] iSono Health company profile | https://tracxn.com/d/companies/isono-health
13. [Crunchbase, 2022] iSono Health funding | https://www.crunchbase.com/organization/isono-health
14. [Hologic] Hologic Completes Acquisition of Delphinus Medical Technologies | https://www.hologic.com/newsroom/press-releases/hologic-completes-acquisition-delphinus-medical-technologies
15. [Seno Medical] Seno Medical Instruments company information | https://senomedical.com/
16. [FDA, 2021] FDA Approves Seno Medical's Imagio Breast Imaging System | https://www.fda.gov/news-events/press-announcements/fda-approves-seno-medicals-imagio-breast-imaging-system